6.
. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010; 59(8):224-9.
View
7.
Lewinsohn D, Leonard M, LoBue P, Cohn D, Daley C, Desmond E
. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017; 64(2):111-115.
PMC: 5504475.
DOI: 10.1093/cid/ciw778.
View
8.
Murphy M, Wilmore S, Satta G, Witney A, Atzeni A, Sturgeon K
. Occupational Tuberculosis despite Minimal Nosocomial Contact in a Health Care Worker Undergoing Treatment with a Tumor Necrosis Factor Inhibitor. Ann Am Thorac Soc. 2016; 13(12):2275-2277.
DOI: 10.1513/AnnalsATS.201608-582LE.
View
9.
Comstock G, Baum C, Snider Jr D
. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979; 119(5):827-30.
DOI: 10.1164/arrd.1979.119.5.827.
View
10.
Dodd P, Gardiner E, Coghlan R, Seddon J
. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014; 2(8):e453-9.
DOI: 10.1016/S2214-109X(14)70245-1.
View
11.
Golub J, Cronin W, Obasanjo O, Coggin W, Moore K, Pope D
. Transmission of Mycobacterium tuberculosis through casual contact with an infectious case. Arch Intern Med. 2001; 161(18):2254-8.
DOI: 10.1001/archinte.161.18.2254.
View
12.
Villarino M, Scott N, Weis S, Weiner M, Conde M, Jones B
. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015; 169(3):247-55.
PMC: 6624831.
DOI: 10.1001/jamapediatrics.2014.3158.
View
13.
Ziakas P, Mylonakis E
. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009; 49(12):1883-9.
DOI: 10.1086/647944.
View
14.
. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005; 54(RR-15):1-47.
View
15.
Njie G, Morris S, Yelk Woodruff R, Moro R, Vernon A, Borisov A
. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Am J Prev Med. 2018; 55(2):244-252.
PMC: 6097523.
DOI: 10.1016/j.amepre.2018.04.030.
View
16.
Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg H, Venkatappa T, Horsburgh C
. Latent tuberculous infection in the United States and Canada: who completes treatment and why?. Int J Tuberc Lung Dis. 2014; 19(1):31-8.
PMC: 5296762.
DOI: 10.5588/ijtld.14.0373.
View
17.
Spyridis N, Spyridis P, Gelesme A, Sypsa V, Valianatou M, Metsou F
. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007; 45(6):715-22.
DOI: 10.1086/520983.
View
18.
Haddad M, Raz K, Lash T, Hill A, Kammerer J, Winston C
. Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011-2015. Emerg Infect Dis. 2018; 24(10):1930-1933.
PMC: 6154166.
DOI: 10.3201/eid2410.180716.
View
19.
Bibbins-Domingo K, C Grossman D, Curry S, Bauman L, Davidson K, Epling Jr J
. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316(9):962-9.
DOI: 10.1001/jama.2016.11046.
View
20.
Machingaidze S, Wiysonge C, Gonzalez-Angulo Y, Hatherill M, Moyo S, Hanekom W
. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J. 2011; 30(8):694-700.
DOI: 10.1097/INF.0b013e318214b915.
View